3 Recession-Proof ETFs to Invest in Now
The U.S. gross domestic product (GDP) contracted 0.3% during the…
Buy
59
DRUG Quote, Financials, Valuation and Earnings
Last price:
$32.58
Seasonality move
:
8.15%
Day range:
$32.04 - $33.65
52-week range:
$0.93 - $79.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.68x
Volume:
23.7K
Avg. volume:
28.6K
1-year change:
2840.27%
Market cap:
$228.9M
Revenue:
--
EPS (TTM):
-$0.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -$0.54 | -- | -233.48% | $93.51 |
|
MIRA
Mira Pharmaceuticals
|
-- | -$0.11 | -- | -13.64% | $17.75 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.21 | 14.03% | -95.43% | $0.85 |
|
NNVC
Nanoviricides
|
-- | -$0.20 | -- | -26.67% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | $1.00 |
|
TOVX
Theriva Biologics
|
-- | -$5.50 | -- | -8.25% | $6.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
$32.49 | $93.51 | $228.9M | -- | $0.00 | 0% | -- |
|
MIRA
Mira Pharmaceuticals
|
$1.22 | $17.75 | $20.5M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.56 | $0.85 | $3.3M | -- | $0.00 | 0% | 0.15x |
|
NNVC
Nanoviricides
|
$1.32 | -- | $20.6M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics
|
$0.17 | $1.00 | $3.6M | -- | $0.00 | 0% | 1.05x |
|
TOVX
Theriva Biologics
|
$0.53 | $6.00 | $1.5M | -- | $0.00 | 0% | 0.63x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -61.227 | -- | -- |
|
MIRA
Mira Pharmaceuticals
|
-- | -2.778 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.186 | 1.51% | 0.75x |
|
NNVC
Nanoviricides
|
-- | 2.080 | -- | -- |
|
OGEN
Oragenics
|
-- | 3.254 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -2.512 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences
|
-- | -$1.2M | -- | -- | -- | -$1.1M |
|
MIRA
Mira Pharmaceuticals
|
-- | -$2.1M | -- | -- | -- | -$1.8M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
NNVC
Nanoviricides
|
-- | -$2.1M | -- | -- | -- | -$2.2M |
|
OGEN
Oragenics
|
-- | -$3.4M | -- | -- | -- | -$2M |
|
TOVX
Theriva Biologics
|
-- | -$4.6M | -- | -- | -- | -$4.7M |
Bright Minds Biosciences vs. Competitors
-
Which has Higher Returns DRUG or MIRA?
Mira Pharmaceuticals has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Mira Pharmaceuticals's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- MIRAMira Pharmaceuticals-- -$0.14 -- -
What do Analysts Say About DRUG or MIRA?
Bright Minds Biosciences has a consensus price target of $93.51, signalling upside risk potential of 187.82%. On the other hand Mira Pharmaceuticals has an analysts' consensus of $17.75 which suggests that it could grow by 1354.92%. Given that Mira Pharmaceuticals has higher upside potential than Bright Minds Biosciences, analysts believe Mira Pharmaceuticals is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences3 0 0 MIRAMira Pharmaceuticals0 1 0 -
Is DRUG or MIRA More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mira Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock DRUG or MIRA?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mira Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Mira Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or MIRA?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Mira Pharmaceuticals quarterly revenues of --. Bright Minds Biosciences's net income of $35.3K is higher than Mira Pharmaceuticals's net income of -$2M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Mira Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus -- for Mira Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K MIRAMira Pharmaceuticals-- -- -- -$2M
-
Which has Higher Returns DRUG or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Bright Minds Biosciences's net margin of -49.65%. Bright Minds Biosciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About DRUG or NBY?
Bright Minds Biosciences has a consensus price target of $93.51, signalling upside risk potential of 187.82%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.71%. Given that Bright Minds Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe Bright Minds Biosciences is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences3 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is DRUG or NBY More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.
-
Which is a Better Dividend Stock DRUG or NBY?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NBY?
Bright Minds Biosciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Bright Minds Biosciences's net income of $35.3K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K NBYNovaBay Pharmaceuticals0.15x -- $2.4M -$1.2M
-
Which has Higher Returns DRUG or NNVC?
Nanoviricides has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Nanoviricides's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- NNVCNanoviricides-- -$0.14 -- -
What do Analysts Say About DRUG or NNVC?
Bright Minds Biosciences has a consensus price target of $93.51, signalling upside risk potential of 187.82%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 392.42%. Given that Nanoviricides has higher upside potential than Bright Minds Biosciences, analysts believe Nanoviricides is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences3 0 0 NNVCNanoviricides0 0 0 -
Is DRUG or NNVC More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.
-
Which is a Better Dividend Stock DRUG or NNVC?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or NNVC?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Bright Minds Biosciences's net income of $35.3K is higher than Nanoviricides's net income of -$2M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K NNVCNanoviricides-- -- -- -$2M
-
Which has Higher Returns DRUG or OGEN?
Oragenics has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- OGENOragenics-- -$0.27 -- -
What do Analysts Say About DRUG or OGEN?
Bright Minds Biosciences has a consensus price target of $93.51, signalling upside risk potential of 187.82%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 493.12%. Given that Oragenics has higher upside potential than Bright Minds Biosciences, analysts believe Oragenics is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences3 0 0 OGENOragenics0 1 0 -
Is DRUG or OGEN More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.
-
Which is a Better Dividend Stock DRUG or OGEN?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or OGEN?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Bright Minds Biosciences's net income of $35.3K is higher than Oragenics's net income of -$3.3M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 1.05x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K OGENOragenics1.05x -- -- -$3.3M
-
Which has Higher Returns DRUG or TOVX?
Theriva Biologics has a net margin of -- compared to Bright Minds Biosciences's net margin of --. Bright Minds Biosciences's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUGBright Minds Biosciences-- $0.01 -- TOVXTheriva Biologics-- -$1.60 -- -
What do Analysts Say About DRUG or TOVX?
Bright Minds Biosciences has a consensus price target of $93.51, signalling upside risk potential of 187.82%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 1032.29%. Given that Theriva Biologics has higher upside potential than Bright Minds Biosciences, analysts believe Theriva Biologics is more attractive than Bright Minds Biosciences.
Company Buy Ratings Hold Ratings Sell Ratings DRUGBright Minds Biosciences3 0 0 TOVXTheriva Biologics1 1 0 -
Is DRUG or TOVX More Risky?
Bright Minds Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.
-
Which is a Better Dividend Stock DRUG or TOVX?
Bright Minds Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG or TOVX?
Bright Minds Biosciences quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Bright Minds Biosciences's net income of $35.3K is higher than Theriva Biologics's net income of -$4.4M. Notably, Bright Minds Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUGBright Minds Biosciences-- -- -- $35.3K TOVXTheriva Biologics0.63x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Butterfly Network the Best Small-Cap Stock?
Brought to public trading by an SPAC merger in early…
Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
